Pentobarbital Pediatric Dose — Sedation
Pentobarbital is a short-acting barbiturate that produces sedation and hypnosis by enhancing GABA-mediated inhibition in the central nervous system. It is used in pediatric practice primarily for procedural sedation and as a premedication prior to diagnostic imaging or invasive procedures. Its reliable onset and predictable depth of sedation make it a useful agent in controlled clinical settings.
Pediatric Dosing
- 2–3 mg/kg per dose IV or IM
- Maximum single dose: 100 mg
Dosing is weight-based and should be individualized based on the patient’s clinical status, level of anxiety, and intended procedure. The dose range of 2–3 mg/kg reflects variation in patient sensitivity and procedural requirements.
Worked example: For a 20 kg child: 20 × 2 mg/kg = 40 mg (low end) to 20 × 3 mg/kg = 60 mg (high end) per dose. For a 40 kg child, the calculated dose would be 80–120 mg; however, the dose should not exceed 100 mg per dose regardless of weight. Consult institutional protocol for repeat dosing intervals and cumulative dose limits.
Indications and Clinical Context
Pentobarbital is indicated for procedural sedation in pediatric patients, particularly for non-painful procedures such as CT or MRI imaging where the child must remain motionless. It may also be used as a preprocedural sedative-hypnotic to reduce patient anxiety and facilitate cooperation. Unlike opioids or propofol, pentobarbital does not provide analgesia; supplemental analgesia should be considered for painful procedures.
Appropriate patient selection is essential. Pentobarbital sedation requires a monitored setting with personnel trained in pediatric airway management, consistent with standard procedural sedation guidelines. It is generally reserved for settings where respiratory support is immediately available.
Administration and Monitoring
Pentobarbital may be administered intravenously or intramuscularly at the stated dose. The IV route allows for more rapid onset and titration; administer IV doses slowly to reduce the risk of respiratory depression and hypotension. IM administration is an alternative when IV access is unavailable. Continuous monitoring of respiratory rate, oxygen saturation, heart rate, and blood pressure is required throughout sedation and during recovery.
- Administer IV doses slowly; rapid injection increases risk of adverse effects
- Maximum single dose: 100 mg regardless of weight
- Monitor for respiratory depression, apnea, and hypotension
- Have airway equipment and resuscitative medications immediately available
- Use with caution in patients with hepatic impairment or those receiving other CNS depressants
- Consult institutional protocol for recovery monitoring duration and discharge criteria
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.